JP2022537736A - １２ｋＤａのＡｐｏＥアミノ末端断片に対する抗体 - Google Patents

１２ｋＤａのＡｐｏＥアミノ末端断片に対する抗体 Download PDF

Info

Publication number
JP2022537736A
JP2022537736A JP2021575056A JP2021575056A JP2022537736A JP 2022537736 A JP2022537736 A JP 2022537736A JP 2021575056 A JP2021575056 A JP 2021575056A JP 2021575056 A JP2021575056 A JP 2021575056A JP 2022537736 A JP2022537736 A JP 2022537736A
Authority
JP
Japan
Prior art keywords
seq
cdr
antibody
antigen
apoe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021575056A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537736A5 (https=
Inventor
シャーロット サーリン，
ヨハンナ フェルティング，
マリア エリクソン，
クリステル メラー，
Original Assignee
バイオアークティック アーベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオアークティック アーベー filed Critical バイオアークティック アーベー
Publication of JP2022537736A publication Critical patent/JP2022537736A/ja
Publication of JP2022537736A5 publication Critical patent/JP2022537736A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021575056A 2019-06-28 2020-06-25 １２ｋＤａのＡｐｏＥアミノ末端断片に対する抗体 Pending JP2022537736A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19183405.0 2019-06-28
EP19183405.0A EP3757125A1 (en) 2019-06-28 2019-06-28 Antibody directed against the apoe amino-terminal fragment of 12 kda
PCT/EP2020/067890 WO2020260491A2 (en) 2019-06-28 2020-06-25 New antibody

Publications (2)

Publication Number Publication Date
JP2022537736A true JP2022537736A (ja) 2022-08-29
JP2022537736A5 JP2022537736A5 (https=) 2023-06-29

Family

ID=67225987

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021575056A Pending JP2022537736A (ja) 2019-06-28 2020-06-25 １２ｋＤａのＡｐｏＥアミノ末端断片に対する抗体

Country Status (11)

Country Link
US (1) US20220242939A1 (https=)
EP (2) EP3757125A1 (https=)
JP (1) JP2022537736A (https=)
KR (1) KR20220029653A (https=)
CN (1) CN114008074A (https=)
AU (1) AU2020304855A1 (https=)
BR (1) BR112021025956A2 (https=)
CA (1) CA3140999A1 (https=)
IL (1) IL289271A (https=)
MX (1) MX2021016160A (https=)
WO (1) WO2020260491A2 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05501400A (ja) * 1989-08-18 1993-03-18 スクリップス　クリニック　アンド　リサーチ　ファウンデーション アポリポタンパクｅのポリペプチド類似体、診断系および該類似体の使用法
JP2009092550A (ja) * 2007-10-10 2009-04-30 Japan Health Science Foundation うつ病またはうつ状態の同定方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ581835A (en) * 2007-06-12 2012-09-28 Ac Immune Sa Monoclonal anti beta amyloid antibody
CN102459335B (zh) * 2009-04-17 2015-11-25 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
WO2011084714A2 (en) * 2009-12-17 2011-07-14 Biogen Idec Ma Inc. STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
US20170218058A1 (en) * 2016-01-28 2017-08-03 Alector, LLC Anti-apoe4 antigen-binding proteins and methods of use thereof
US20190224339A1 (en) * 2016-04-29 2019-07-25 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2018137705A1 (en) * 2017-01-26 2018-08-02 Zai Lab (Shanghai) Co., Ltd. Cd47 antigen binding unit and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05501400A (ja) * 1989-08-18 1993-03-18 スクリップス　クリニック　アンド　リサーチ　ファウンデーション アポリポタンパクｅのポリペプチド類似体、診断系および該類似体の使用法
JP2009092550A (ja) * 2007-10-10 2009-04-30 Japan Health Science Foundation うつ病またはうつ状態の同定方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIOCHEM. J., vol. 366, JPN6024026770, 2002, pages 273 - 279, ISSN: 0005366149 *
化学と生物, vol. 47, no. 6, JPN6021033115, 2009, pages 436 - 440, ISSN: 0005519450 *
病気がみえる VOL.6 免疫・膠原病・感染症, vol. 第2版, JPN6024026769, 2018, pages 15, ISSN: 0005519451 *

Also Published As

Publication number Publication date
AU2020304855A1 (en) 2021-12-23
EP3757125A1 (en) 2020-12-30
BR112021025956A2 (pt) 2022-02-08
IL289271A (en) 2022-02-01
US20220242939A1 (en) 2022-08-04
CN114008074A (zh) 2022-02-01
CA3140999A1 (en) 2020-12-30
MX2021016160A (es) 2022-04-06
EP3990486A2 (en) 2022-05-04
KR20220029653A (ko) 2022-03-08
WO2020260491A2 (en) 2020-12-30
WO2020260491A3 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
KR102695287B1 (ko) 항-phf-타우 항체 및 이의 용도
JP7837375B2 (ja) ピログルタメートアミロイド－βに対する抗体及びその使用
KR101981351B1 (ko) 타우를 인식하는 포스포특이적 항체
Altay et al. Development and validation of an expanded antibody toolset that captures alpha-synuclein pathological diversity in Lewy body diseases
JP7829171B2 (ja) ミスフォールドｔｄｐ－４３に対する抗体およびその使用方法
CN115697393A (zh) 抗PHF-tau抗体及其用途
KR20250134612A (ko) Abetape3에 결합하는 항체
JP2022537736A (ja) １２ｋＤａのＡｐｏＥアミノ末端断片に対する抗体
WO2025047850A1 (ja) 神経変性疾患の治療剤
JP2023519007A (ja) Ａｒｅｇに対する抗体及びその用途
EA049614B1 (ru) Анти-псф-тау-антитела и способы их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211217

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20211217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230619

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230619

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240709

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240815

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250204